The comparable relapse-free survival between FLT3-ITD and wild-type FLT3 AML patients in our study differs from some previous reports that have shown a higher risk of relapse in FLT3-ITD AML (4, 5). The gene discussed is FLT3; the disease is acute myeloid leukemia.